Stockscreener 앱 받기
75.03
0.43%
0.32
시간 외 거래:
75.03
Cg Oncology Inc 주식(CGON)의 최신 뉴스
CGON shareholder (NASDAQ: CGON) details planned 19,364-share stock sale - Stock Titan
CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds - Stock Titan
Midday Stock Roundup: Mobix Labs Shares Fall 21% at Midday - Orange County Business Journal
CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares - Stock Titan
CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects. - Pluang
CG Oncology Stock: Circling Back After Huge Rally (NASDAQ:CGON) - Seeking Alpha
CGON (CGON) investor lists 25,989-share sale after series of stock disposals - Stock Titan
CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position - Stock Titan
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $85 - moomoo.com
CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise - Stock Titan
CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale - Stock Titan
CG Oncology (NASDAQ:CGON) Hits New 52-Week HighShould You Buy? - MarketBeat
CG Oncology, Inc. (CGON) Stock Analysis: A Potential 18.96% Upside In The Biotech Sector - DirectorsTalk Interviews
CGON (CGON) insider plans 50,000-share stock sale after option exercise - Stock Titan
HC Wainwright Has Weak Estimate for CG Oncology Q3 Earnings - MarketBeat
CG Oncology Inc (CGON) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $85 to $108 - Moomoo
Enterprise value to EBITDA forward of CG Oncology, Inc. – NASDAQ:CGON - TradingView
Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON) - The Globe and Mail
Bank of America Corp DE Grows Holdings in CG Oncology, Inc. $CGON - MarketBeat
Wall Street Zen Downgrades CG Oncology (NASDAQ:CGON) to Strong Sell - MarketBeat
CG Oncology (NASDAQ:CGON) Posts Earnings Results, Misses Expectations By $0.24 EPS - MarketBeat
Insider Ambaw Bellete plans CGON (CGON) stock sale after large prior trades - Stock Titan
Royal Bank Of Canada Has Lowered Expectations for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
Piper Sandler Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
Truist Financial Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price - MarketBeat
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $79 to $100 - moomoo.com
BofA Adjusts Price Target on CG Oncology to $88 From $87 - Moomoo
RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating - marketscreener.com
FY2029 EPS Estimates for CG Oncology Cut by HC Wainwright - MarketBeat
How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data - simplywall.st
CG ONCOLOGY Q2 NET INCOME USD -79.1 MILLION - Moomoo
CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside - TradingView
Insider (NASDAQ: CGON) files to sell 75,000 shares after recent stock sales - Stock Titan
CG Oncology earnings up next amid bladder cancer therapy push By Investing.com - Investing.com Nigeria
CG Oncology earnings up next amid bladder cancer therapy push - Investing.com
CG Oncology Announces Q2 2026 Financial Results with Increased Revenues and Expanded Marketable Securities - Kalkine Media
CG Oncology Announces Q2 2026 Earnings and Boosts ATM Equity Offering by $500 Million - Kalkine Media
CG Oncology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CG Oncology Q2 Net Loss Widens - marketscreener.com
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.90 a Share, vs. FactSet Est of $0.66 Loss - marketscreener.com
Earnings Flash (CGON) CG Oncology, Inc. Reports Q2 Revenue $1.2M - marketscreener.com
CG Oncology (NASDAQ: CGON) posts $139.3M half-year loss with $1,028.3M cash - Stock Titan
CG Oncology posts Q2 loss as bladder cancer milestones approach - Quiver Quantitative
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
CG Oncology Q2 net loss widens on higher R&D costs - TradingView
CG Oncology expects bladder cancer trial data soon; cash through 2029 - Stock Titan
CG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programs - Bitget
CGON (CGON) insider Ambaw Bellete plans 25,000-share stock sale via broker - stocktitan.net
Dimensional Fund Advisors LP Sells 22,459 Shares of CG Oncology, Inc. $CGON - MarketBeat
Price to book forward of CG Oncology, Inc. – NASDAQ:CGON - TradingView
Investors Purchase Large Volume of Call Options on CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology, Inc. (CGON) Stock Analysis: Potential 31.15% Upside In Biotech Sector - DirectorsTalk Interviews
CG Oncology, Inc. $CGON Shares Sold by Avidity Partners Management LP - MarketBeat
CG Oncology (CGON) to Post Earnings on Friday - MarketBeat
Form 144 CG ONCOLOGY For: 30 July By Investing.com - Investing.com Nigeria
First Trust Advisors LP Boosts Stake in CG Oncology, Inc. $CGON - MarketBeat
CG Oncology stock maintained at Buy by H.C. Wainwright on trial data - Investing.com Canada
What CG Oncology (CGON)'s Pivotal BOND-003 Phase 3 Data Means For Shareholders - Sahm
Why Does CG Oncology (NASDAQ:CGON) Stock Matter in the Healthcare Stocks Conversation Now? - Kalkine Media
CG Oncology Inc (CGON) Institutional Confidence - TradingKey
CG Oncology, Inc. (CGON) Stock Analysis: Exploring a 23% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology - The Manila Times
CG Oncology bladder cancer trial results published in Lancet By Investing.com - Investing.com Canada
CG Oncology bladder cancer trial results published in Lancet - Investing.com
CG Oncology Announces Lancet Oncology Publication of Phase 3 BOND-003 Cohort C Results for Cretostimogene in High-Risk BCG-Unresponsive Bladder Cancer - Quiver Quantitative
About 81% of BOND-003 patients maintained their bladders at 24 months - Stock Titan
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology - GlobeNewswire Inc.
0.52%
0.07%
자본화:
|
볼륨(24시간):